Stephan Jackman - Alzamend Neuro CEO Director
| ALZN Stock | USD 0.69 0.02 2.99% |
Insider
Stephan Jackman is CEO Director of Alzamend Neuro
| Age | 49 |
| Phone | 844 722 6333 |
| Web | https://www.alzamend.com |
Stephan Jackman Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephan Jackman against Alzamend Neuro stock is an integral part of due diligence when investing in Alzamend Neuro. Stephan Jackman insider activity provides valuable insight into whether Alzamend Neuro is net buyers or sellers over its current business cycle. Note, Alzamend Neuro insiders must abide by specific rules, including filing SEC forms every time they buy or sell Alzamend Neuro'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephan Jackman over a year ago Purchase by Stephan Jackman of 37000 shares of Alzamend Neuro |
Alzamend Neuro Management Efficiency
The company has return on total asset (ROA) of (1.2164) % which means that it has lost $1.2164 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (10.9296) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Jim Wang | Adverum Biotechnologies | N/A | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Kerry MD | Terns Pharmaceuticals | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Charles II | Day One Biopharmaceuticals | 47 | |
| MSc MBA | Inozyme Pharma | 53 | |
| MS MBA | Inozyme Pharma | 48 | |
| Mark Vignola | Terns Pharmaceuticals | 47 | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Russell MS | Acumen Pharmaceuticals | 67 | |
| Nancy Pecota | Adverum Biotechnologies | 64 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
| Clare MBA | Alector | N/A | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Fangyong Du | Adagene | 54 | |
| Michael Wolfe | Kezar Life Sciences | N/A | |
| Paul Herzich | Solid Biosciences LLC | 47 | |
| Caitlin Lowie | Solid Biosciences LLC | N/A | |
Management Performance
| Return On Equity | -10.93 | ||||
| Return On Asset | -1.22 |
Alzamend Neuro Leadership Team
Elected by the shareholders, the Alzamend Neuro's board of directors comprises two types of representatives: Alzamend Neuro inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alzamend. The board's role is to monitor Alzamend Neuro's management team and ensure that shareholders' interests are well served. Alzamend Neuro's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alzamend Neuro's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kenneth CPA, Senior Finance | ||
| David Katzoff, Chief Officer | ||
| Stephan Jackman, CEO Director | ||
| Milton III, Founder Chairman | ||
| Henry Esq, General VP |
Alzamend Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alzamend Neuro a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.93 | ||||
| Return On Asset | -1.22 | ||||
| Current Valuation | 4.53 M | ||||
| Shares Outstanding | 6.6 M | ||||
| Shares Owned By Insiders | 3.08 % | ||||
| Shares Owned By Institutions | 1.71 % | ||||
| Number Of Shares Shorted | 52.81 K | ||||
| Price To Book | 1.23 X | ||||
| EBITDA | (9.89 M) | ||||
| Net Income | (9.95 M) |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.